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A B S T R A C T
Background
Pancreatic cancer is a deadly disease. Discovery of the mutated genes that cause the
inherited form(s) of the disease may shed light on the mechanism(s) of oncogenesis. Previously
we isolated a susceptibility locus for familial pancreatic cancer to chromosome location 4q32–
34. In this study, our goal was to discover the identity of the familial pancreatic cancer gene on
4q32 and determine the function of that gene.
Methods and Findings
A customized microarray of the candidate chromosomal region affecting pancreatic cancer
susceptibility revealed the greatest expression change in palladin (PALLD), a gene that encodes
a component of the cytoskeleton that controls cell shape and motility. A mutation causing a
proline (hydrophobic) to serine (hydrophilic) amino acid change (P239S) in a highly conserved
region tracked with all affected family members and was absent in the non-affected members.
The mutational change is not a known single nucleotide polymorphism. Palladin RNA,
measured by quantitative RT-PCR, was overexpressed in the tissues from precancerous
dysplasia and pancreatic adenocarcinoma in both familial and sporadic disease. Transfection of
wild-type and P239S mutant palladin gene constructs into HeLa cells revealed a clear
phenotypic effect: cells expressing P239S palladin exhibited cytoskeletal changes, abnormal
actin bundle assembly, and an increased ability to migrate.
Conclusions
These observations suggest that the presence of an abnormal palladin gene in familial
pancreatic cancer and the overexpression of palladin protein in sporadic pancreatic cancer
cause cytoskeletal changes in pancreatic cancer and may be responsible for or contribute to
the tumor’s strong invasive and migratory abilities.
The Editors’ Summary of this article follows the references.
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Introduction
Pancreatic adenocarcinoma is the fourth leading cause of
cancer death in the United States, and the third leading cause
in individuals aged 40–59 years [1]. Pancreatic cancer is
difﬁcult to detect, resistant to treatment, and is usually
discovered after it has metastasized. Nearly every person who
develops pancreatic cancer will die from it, the majority
within the ﬁrst year of diagnosis [2]. The identiﬁcation of
high-risk individuals and elucidation of key oncogenic path-
ways are therefore priorities for scientists and physicians
hoping to change this cancer’s dismal prognosis.
Familial clustering of pancreatic cancers is commonly
recognized, occurring in at least 10% of all pancreatic cancer
[3,4]. The risk of pancreatic cancer increases with each family
member who is affected [5,6]. Growing evidence suggests that
some apparently sporadic pancreatic cancers are actually
caused by inherited genetic susceptibility [4]. Pancreatic
cancer can also be inherited as part of a familial cancer
syndrome such as that associated with BRCA2 mutations,
Peutz-Jeghers syndrome, and familial atypical mole and
melanoma syndrome [4]. In those cases, the family pedigree
shows evidence of other cancers such as breast or intestinal
tumors, or melanomas, in addition to pancreatic tumors. The
vast majority of familial pancreatic cancer is not accounted
for by such known cancer syndromes. Discovery of a gene (or
genes), that when mutated in the germline cause heritable
pancreatic adenocarcinoma, could provide important in-
sights into the biology of the pancreatic cancers, and
potentially of non-pancreatic cancers as well. Such discov-
eries have been difﬁcult because the rapid demise of
pancreatic cancer patients hampers collection of biological
samples for genotyping.
We previously reported an exceptional family, Family X, in
which pancreatic adenocarcinoma is inherited in an autoso-
mal dominant fashion with high penetrance [7]. In order to
identify living carrier family members prior to the onset of
cancer, we developed an endoscopic surveillance program
that assists in the detection of pancreatic precancerous
dysplasia [8,9]. This condition, also called pancreatic intra-
epithelial neoplasia (PanIN), is the precancerous lesion of
both sporadic and familial pancreatic cancers. PanIN is
graded from 1 to 3 with increasing neoplastic progression:
hyperplasia (PanIN 1) to low-grade dysplasia (PanIN 2) to
carcinoma in situ (PanIN 3). PanIN lesions of all three grades
are prominent throughout the pancreatic tissue of affected
Family X members prior to cancer formation [10]. Through
our pancreatic cancer surveillance program we were able to
identify the members of Family X who had impending cancer
formation (histologic conformation of PanIN 2 and 3 in the
pancreas). This program allowed us to identify the patients at
a curable stage of their disease and to genotype them.
Four generations of Family X include 18 cases of either
adenocarcinoma (n¼9) or histologically proven precancerous
PanIN 2 and 3 (n ¼ 9) (Figure 1). Through genotyping of 35
family members, a pancreatic adenocarcinoma susceptibility
locus was previously mapped to the chromosomal location
4q32–34 [11]. The work to identify the gene of interest in this
region has been a considerable challenge because of the size
(16 Mb) and the number of genes (approximately 250)
localized to this region [12]. We now report the identiﬁcation
of this familial pancreatic cancer gene and the assessment of
that gene’s involvement in familial and sporadic pancreatic
cancer.
Methods
Biological Samples
All human samples (blood, pancreas, and constitutional
tissues such as duodenum and lymph nodes) were collected
and used under protocols approved by the Institutional
Review Board at the University of Washington (Seattle,
Washington, United States) and the University of Pittsburgh.
Family X is of western European descent. In this kindred,
pancreatic adenocarcinoma is inherited in an autosomal
dominant fashion with high penetrance [7]. All study
participants from Family X or other familial pancreatic
cancer kindreds were ascertained at the University of
Washington, with additional samples from patients without
cancer (controls) or with pancreatic adenocarcinoma from all
participating institutions.
Additional normal pancreas samples were obtained com-
mercially from Stratagene (La Jolla, California, United
States), Clontech (Mountain View, California, United States),
Biochain (Hayward, California, United States), Chemicon
(Temecula, California, United States), and Ambion (Austin,
Texas, United States). Surgically resected pancreatic tissue
samples were snap-frozen in liquid nitrogen or on dry ice
Figure 1. Family X Pedigree
Nine members of this family were diagnosed with pancreatic cancer and nine with pancreatic precancer (five with carcinoma in situ [PanIN 3] and four
with low-grade dysplasia [PanIN 2]).
doi:10.1371/journal.pmed.0030516.g001
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immediately after gross identiﬁcation and approval by the
clinical pathologists responsible for the cases. Adjacent and
representative frozen sections and ﬁxed sections were
analyzed and pathological diagnosis made by a qualiﬁed
pathologist (MPB). Tissue samples remained frozen at80 8C
until use. In addition, pancreatic cancer cell lines (FA6,
HPAF, PANC 1, HS766T, IMMPC2, SUIT 2, and PATU2) were
obtained courtesy of Dr. Nicholas Lemoine (Molecular
Oncology Unit, Cancer Research United Kingdom, Barts,
and the London School of Medicine and Dentistry, London,
United Kingdom) and author TCJ. The human pancreatic
ductal epithelium (HPDE) cell line was obtained courtesy of
Dr. Ming-Sound Tsao (Department of Medical Biophysics,
University of Toronto, Toronto, Ontario, Canada).
Custom Microarrays
Unigenes represent a nonredundant set of gene-oriented
clusters of cDNA clones assigned to a unique gene and/or
genomic location. Unigenes for this study were identiﬁed
using the UCSC genome maps (draft sequence 12/01) (http://
genome.ucsc.edu/cgi-bin/hgGateway/) and NCBI maps. We
identiﬁed 243 Unigene clones mapping between markers
D4S413 and D4S299. Seventeen clones were included as
housekeeping genes and 25 additional clones were included
because of their location in a region of the genome that is
frequently lost in pancreatic cancer. Clones were acquired
from Research Genetics (now Invitrogen, Carlsbad, Califor-
nia, United States), from RZPD (German Resource Center for
Genome Research, Berlin, Germany), and from the University
of Pittsburgh Genomics and Proteomics Core Laboratories
(Pittsburgh, Pennsylvania, United States). Identiﬁcation of all
clones and accurate locations on chromosome 4q were
conﬁrmed by DNA sequence. Clones were ampliﬁed, puriﬁed,
and arrayed onto glass slides in sextuplicates as previously
described [13].
Hybridization
Slides were scanned with a GMS 418 scanner (Genetic
MicroSystems brand, Affymetrix, Santa Clara, California,
United States). The Cy-5 and Cy-3 images were overlaid, and
raw data were generated for both channels using the
ImaGene program United (Bioinformatics, Calgary, Alberta,
Canada). Microarray analysis was performed using the Gene
Expression Differential Analysis tool (caGEDA), a web
application speciﬁcally developed for cancer microarray data
analysis (http://bioinformatics.upmc.edu/GE2/GEDA.html)
[14].
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was carried out using the
59 nuclease assay and an Applied Biosystems 7700 Sequence
Detection Instrument (with TaqMan) (http:/ /www.
appliedbiosystems.com). Expression analysis utilized whole
tissues. Palladin (PALLD) expression was measured relative to
the endogenous control, GAPDH, using the comparative CT
method described previously [15]. The cDNAs were generated
at two different RNA input concentrations (10 ng/ll and 4 ng/
ll) and TaqMan reactions with the endogenous control were
run in duplicate from both RT reactions. Palladin TaqMan
reactions were performed in triplicate using RT reactions
with 10 ng/ll reactions. A calibrator RNA composed of 50 ng/
ll universal reference RNA (Stratagene; #40000–41) and 50
ng/ll colon RNA (Ambion; #7986) was included on every
ampliﬁcation plate to allow for the comparison of samples
run at different times. RT-negative controls were run on each
plate to ensure that no ampliﬁcation occurred in the absence
of cDNA. Primers were purchased from Applied Biosystems
(Hs99999905_m1 for GAPDH and Hs00363100_m1 for
palladin).
Statistical Analysis
We used the J5 test and normalized the data with log2 and Z
transformation as previously described [14]. The J5 test
compares the difference in mean expression for a given gene
to the magnitude (absolute value) of mean difference in all of
the genes on an array. To evaluate group differences on qRT-
PCR statistically, an overall one-way, 4-group analysis of
variance was performed. Pairwise group comparisons were
analyzed using Fisher’s least squares difference test with a
signiﬁcance level of p , 0.05.
DNA Sequencing of Candidate Genes
While development of the custom microarray was under-
way, we identiﬁed 22 potential candidate genes in the 4q32–
34 region and prioritized them according to the likelihood
that they play a role in pancreatic neoplastic transformation.
Twenty of the genes were sequenced in entirety, while the last
two genes were partially sequenced because the palladin gene
mutation had been discovered (Table 1). Primers and PCR
conditions for these 22 genes are available upon request.
Sequencing was carried out with the Big Dye V3.1 kit (ABI,
Foster City, California, United States).
Copy Number Assessment of Palladin
We used a custom-manufactured high-density palladin array
to assess the copy number of palladin in dysplastic tissue
(NimbleGen Systems, Madison, Wisconsin, United States).
The sequence of palladin was tiled with oligonucleotides that
started every 60 bp. Comparative genomic hybridization was
performed using genomic DNA from fresh frozen samples of
PanIN 2 tissue and matching lymphocytes from two separate
Family X members. Pancreatic ductal epithelial cells were
puriﬁed from pancreatic tissue samples by using epithelial
antibody EpCAM and magnetic beads according to the
manufacturer’s instructions (CELLection Epithelial Enrich
Kit; Dynal, Oslo, Norway). The DNA puriﬁed from the
samples was hybridized to the high-density palladin array by
the NimbleGen Service Laboratory. Fluorescence intensity
raw data were obtained from scanned images of the
oligonucleotide tiling arrays by using Nimblescan 2.0 extrac-
tion software and the results were analyzed at the NimbleGen
Service Laboratory.
Protein Analysis by Western Blot
Size fractionation (SDS-PAGE) was performed on 20 lg of
protein from each pancreatic cell line sample. The samples
were individually loaded onto a gel, separated through
electrophoresis, and then blotted onto a nitrocellulose
membrane according to manufacturer’s protocol (Amersham
Biosciences, Piscataway, New Jersey, United States). The
polyclonal palladin antibody (ab 621) was created as
previously described [16]. A 1:2,000 dilution was used for
Western blotting. The ECL plus kit (Amersham Biosciences)
was used to detect protein in the Western blot.
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Palladin Constructs
The human wild-type (WT) palladin construct was made by
PCR-cloning the entire coding sequence from a human
palladin cDNA clone (human cDNA clone hk07554, a gift from
Dr. Takahiro Nagase of Kazusa DNA Research Institute) into
the sites of EcoRI and BamHI of phrGFP IIN vector
(Stratagene), downstream of, and in frame with, the green
ﬂuorescent protein (GFP) tag. To create the Family X mutant
construct (FX), we used Quick-Change Multi Site-Directed
Mutagenesis (Stratagene) with primers centered at the Family
X mutation (P239S), according to manufacturer’s protocol.
Brieﬂy, (1) 100 ng of WT construct was added as a template to
a PCR cocktail containing 2.5 ll of 103 mutagenesis buffer,
100 ng of mutagenesis primer containing the Family X
mutation, 250 lM each dNTP, 1 ll QuickChange enzyme
blend and 1 ll QuickSolution. The PCR cycling parameters
were one cycle of: 1 min at 95 8C, followed by 30 cycles of 1
min at 95 8C, and 15 min at 65 8C; (2) the parental template
DNA was treated with DpnI (10 U) at 37 8C for 60 min; (3) 4 ll
of this reaction was transformed into XL10 Gold Ultra-
competent cells (Stratagene); and (4) several clones were
chosen for PCR and/sequencing to conﬁrm the incorporation
of the mutation.
HeLa Cell Transfection with Wild-Type and Mutated
Palladin
Transfection was performed using a Fugene kit (Roche
Diagnostics [http://www.rochediagnostics.com]) on human
cancer epithelial cell lines (HeLa cells) according to the
manufacturer’s protocol. Brieﬂy, (1) one day before the
transfection, the cells were distributed into a six-well plate so
that they would be approximately 70% conﬂuent the next
day; (2) 3–6 ll of transfection reagent was mixed with 94–97 ll
of DMEM and left for 5 min; (3) then 1 lg of construct (either
WT or FX mutant construct) was added to the complex and
left for 10 min; (4) the complex was then added to the cells in
a dropwise fashion; and (5) the expression of the GFP
construct was observed the next day. Fluorescence staining
was performed on cells ﬁxed in 3.7% formaldehyde and
permeabilized with 0.1% Triton X-100. The cells were then
stained with 50 lg/ml of TRITC-phalloidin (Sigma) for 40
min, followed by washing with PBS. Finally, DAPI (Sigma) was
added at 10 lg/ml to stain the nucleus, and antifade reagent
(Invitrogen) was used to prevent auto-color bleaching. The
construct/transfection experiments were run in triplicate and
assessed blindly by the senior author.
Cell Migration Assay
HeLa cells were ﬁrst transfected with constructs of WT, FX,
and empty vector respectively for 24 h, and then sorted for
GFP-positive cells. The sorted cells continued to grow for 2 d
before they were seeded onto a transwell plate for the
migration assay. Migration assays were performed on 24-well
Transwell cell culture chambers (Corning Costar Corpora-
tion, Cambridge, Massachusetts, United States) ﬁtted with
multiporous (8-lm pore size) polycarbonate membranes. The
upper chambers of the membrane were coated with
ﬁbronectin (10 lg/ml in PBS) 24–48 h before the assay. The
upper chamber was then ﬁlled with 40,000 cells in suspension
with 400 ll of medium (DMEM with 10% FCS), and the lower
chamber was ﬁlled with 500 ll of the same medium. Plates
were placed in a humidiﬁed CO2 incubator at 37 8C for 17 h.
Table 1. Candidate Genes Sequenced in Region 4q32–34
Gene Description Function
ANXA10 Annexin A10 Regulation of cellular growth and in signal transduction pathways
FBXO8 F-box only protein 8 Subunit of ubiquitin protein ligase
HHIP Hedgehog-interacting protein family member Inhibits Hedgehog pathway
VEGFC Vascular endothelial growth factor C Active in angiogenesis and endothelial cell growth, and permeability of blood
vessels
SAP30 Sin3-associated polypeptide Active in deacetylating core histone octamers
SFRP2 Secreted Frizzled-related protein 2 Member of the Frizzled protein family; controls cell polarity and malignant trans-
formation.
MORF4 Mortality factor 4 Induces a senescent-like phenotype in cell lines assigned to complementation
group B
POSH SH3 domain containing ring finger Protein involved in the c-Jun N-terminal kinase and nuclear factor-kappa B signal-
ing
HPGD Hydroxy prostaglandin dehydrogenase Inactivates many prostaglandins by oxidation of their C-15 residues
KIAA1712 Antisense to FBXO8 Unknown
GRIA2 Glutamate receptor, ionotropic, AMPA 2 Extracellular ligand-binding receptor
PDZ-GEF1 PDZ domain containing guanine nucleotide exchange factor 1 Regulation of G protein-linked guanine nucleotide exchange factors for Rho and
PDZ-RhoGEF
NEK1 NIMA (never in mitosis gene a) related kinase 1 Regulates signaling pathways of diverse cellular processes
ANP32C Acidic leucine-rich nuclear phosphoprotein 32 Tumor suppressor in prostate cancer
CASP3 Caspase 3 Activates apoptosis
CPE Carboxypeptidase E family zinc carboxypeptidase Cleaves C-terminal amino acid residues; involved in neuropeptide processing
TLL1 Tolloid-like 1 Involved in proteolysis and peptidolysis
CLCN3 Chloride channel 3 Mediates swelling-activated plasma membrane currents
p23 Predicted similar to inactive progesterone receptor Likely ortholog of mouse telomerase binding protein, p23
KIAA0992 Palladin Cytoskeletal protein
HAND2* Heart and neural crest derivatives expressed 2 Cardiac morphogenesis
GLRA3* Glycine receptor alpha-3 Role in neuronal transmission
doi:10.1371/journal.pmed.0030516.t001
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Membrane inserts were then removed, ﬁxed by immersing in
ethanol ﬁve times with 1 s durations, and stained with 0.5%
crystal violet dye (Sigma; #C3886) in 20% methanol for 30
min. After gentle rinsing with water, the nonmigratory cells
on the upper surface of the membrane were removed with
cotton swabs, leaving only the migratory cells within the
membrane. The membrane insert was left to dry overnight
and then placed in a 96-well plate. The dye was extracted with
30% acetic acid and the plate was placed on a shaker for 10
min to allow the dye to dissolve completely. The colorimetric
absorbance was assessed at 590 nm. A transwell without cells
was used as a background control. To correct for the cell
numbers seeded in each transwell experiment, we measured
the optical density of all the original cells in the transwell
(migrated and nonmigrated) for each transfected cell type
sample. By comparing the optical density from each sample
type, we were able to provide a correction factor for any
variation in starting cell number between samples. Each
sample was done in triplicate.
Results
Microarray Expression Analysis Selects Palladin as the
Candidate Familial Pancreatic Cancer Gene
Sequencing of candidate genes in the 4q32–34 region was
time-consuming and ultimately unsuccessful (see Candidate
Gene Sequencing, below). In order to better identify the most
promising candidate genes we employed a new strategy. We
hypothesized that a mutated gene is best detected in very
early precancerous dysplastic tissue, where the mutated gene
has initiated neoplastic transformation but before the over-
arching genetic chaos of cancer has occurred. Theoretically,
the abnormal gene expression would become apparent, from
a molecular standpoint, as the pancreas began to undergo
malignant degeneration. If the gene were a tumor suppressor
gene, we hypothesized that expression would be lost; if it were
a proto-oncogene, expression would increase. To perform the
expression analysis, we narrowed the search to expressed
sequence tags that were densely mapped to our region of
interest. This approach would allow us to interrogate a large
amount of closely spaced DNA with one assay. RNA was
puriﬁed from whole tissue samples containing PanIN 1 from
a Family X member, from two normal pancreas (controls),
and from ten sporadic pancreatic cancers. The RNA samples
were separately proﬁled on a custom expression microarray
to identify gene expression in the 4q32–34 region. The
custom microarray was created using 243 sequence-veriﬁed
Unigene clones located between markers D4S2976 and
D4S415, a region slightly larger than the region identiﬁed
as the pancreatic cancer susceptibility locus (between
markers D4S413 and D4S2991). The Unigene clones were
spotted in sextuplicates (63).
As noted above, a total of 13 RNA samples from pancreatic
Figure 2. Overexpression of Palladin RNA in Sporadic Pancreatic Cancer and in Family X Precancer
(A) To narrow down candidate genes we constructed custom 4q32–34 microarrays composed of 243 expressed sequence tags (IMAGE clones), each of
which was spotted six times on the array. The microarrays were hybridized with RNA derived from the following target tissues: sporadic pancreatic
adenocarcinoma (n¼ 10), Family X pancreatic precancer (n¼ 1), and normal donor pancreas (n¼ 2). Each target tissue was hybridized separately on the
arrays and compared to normal pancreas. This array image is representative of one of the sporadic cancer samples versus normal pancreas. Note the
consistency of the expression of the six spotted replicates of cDNA clones. Green indicates genes that were underexpressed in cancer compared to
normal pancreas; red indicates genes that were overexpressed in cancer compared to normal pancreas, and yellow indicates genes that were expressed
in similar levels as normal pancreas.
(B) The most overexpressed clones among ten sporadic pancreatic cancers were two different palladin clones; both of these clones were significantly
overexpressed in Family X precancer.
(C) RNA overexpression of palladin was confirmed by qRT-PCR. Samples tested were whole pancreatic tissues and included six new normal pancreas
samples, four new precancerous tissues (PanIN 2 and 3, or low- and high-grade dysplasia, respectively) from two Family X individuals and two unique
familial pancreatic cancer individuals not from Family X, nine histologically normal tissues adjacent to cancer, and 16 new pancreatic cancer tissues. In
each case, palladin expression was measured relative to the endogenous standardized control, GAPDH. Error bars indicate 1 standard deviation above
and below the average. Palladin RNA is overexpressed early in the process of pancreatic neoplasia, as it is overexpressed in normal-appearing tissue
adjacent to sporadic cancer, as well as in precancerous pancreatic tissue. In addition, palladin is overexpressed in the precancerous tissue from three
different familial pancreatic cancer kindreds (Family X and two other familial pancreatic cancer kindreds).
doi:10.1371/journal.pmed.0030516.g002
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tissue were proﬁled (Figure 2A). Comparative expression in
Family X and the ten sporadic pancreatic adenocarcinoma
samples were rank-ordered by their degree of over- or
underexpression. Two palladin clones (Unigene [http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db¼unigene] accession
number KIAA0992) were the most highly overexpressed
Unigenes in the ten sporadic pancreatic cancers, and the
same clones were also abnormally expressed in the Family X
precancerous sample as well, based on a J5 analysis as
previously described (Figure 2B) [14]. Palladin clones were also
shown to be among the most overexpressed genes when we
analyzed palladin expression by N-fold analysis in Family X
and sporadic pancreatic cancers compared to normal
pancreas. The overexpression of palladin in sporadic cancer
was higher compared to the Family X precancerous tissue.
Palladin RNA is Overexpressed Very Early in the Process of
Pancreatic Neoplasia
To validate the ﬁndings on the custom microarray, primers
directed toward exons 9 and 10 were used to measure
expression of the palladin gene in whole tissue (Figure 2C).
Expression analysis via qRT-PCR was performed in whole
pancreas tissue from (1) 16 sporadic pancreatic cancers, (2)
four precancerous tissues (two from Family X and two from
other familial pancreatic cancer kindreds), (3) nine histolog-
ically normal-appearing tissues adjacent to sporadic pancre-
atic adenocarcinoma (called ‘‘normal adjacent’’), and (4) six
normal pancreas samples. Palladin was overexpressed in all of
the cancerous and precancerous dysplastic pancreatic tissue,
as well as in the histologically normal-appearing tissue
adjacent to the cancers when compared to normal pancreas.
A signiﬁcant difference in palladin expression levels was
detected between normal pancreata and all of the other three
groups (cancer, precancer, and normal adjacent): pairwise
tests using least signiﬁcant difference test (p , 0.05); one way-
four group ANOVA F (3,31)¼ 5.86, p¼ 0.003. This expression
analysis of 35 samples, composed of normal (n ¼ 6) and
increasingly neoplastic pancreatic tissue (n ¼ 29), indicated
that palladin RNA was overexpressed very early in the
development of pancreatic cancer—in normal-appearing
whole tissue immediately adjacent to cancer, in the pre-
cancer, and in the cancer—of both familial and sporadic
forms of the disease.
Figure 3. Location and Identification of the Family X Mutation
Top black bar indicates the genomic location of the Family X mutation between microsatellite markers D4S413 and D4S299 on Chromosome 4. The
center line designates the location of the palladin transcript, AB023209, with vertical boxes and lines indicating exons. At the bottom, a small portion of
the cDNA sequence shows a C to T base pair change at position 715 (indicated with an arrow), which causes a proline (hydrophobic) to serine
(hydrophilic) amino acid change at amino acid 239 (P239S). This location is the essential binding site for alpha-actinin, another key cytoskeletal protein.
doi:10.1371/journal.pmed.0030516.g003
Figure 4. The Binding Site of Alpha-Actinin to Palladin is Highly
Conserved across Species
The mutation in Family X causes a proline (hydrophobic) to serine
(hydrophilic) change in the human amino acid sequence.
doi:10.1371/journal.pmed.0030516.g004
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Candidate Gene Sequencing Reveals a Mutation in the
Palladin Gene
While construction of the custom array was taking place,
we sequenced some of the candidate genes in the 4q32–34
region selected by their potential role in neoplastic trans-
formation or dysregulation of the pancreas; sequencing of the
candidate genes was performed by using constitutional DNA
from two affected members of Family X. Twenty genes were
fully sequenced and two were partially sequenced (Table 1).
When palladin was identiﬁed by the custom microarray as the
most abnormally expressed gene, it was the twentieth and
ﬁnal gene that was fully sequenced. Only palladin had a gene
mutation; all of the other 19 candidate genes were wild-type.
Mutation in Palladin Tracks Only with the Affected
Members in Family X and Causes an Amino Acid Change
in the Alpha-Actinin Binding Site
Palladin is an extremely large gene spanning 432 Kb, with a
total of 31 exons, up to nine probable alternative promoters,
and at least eight alternatively spliced transcripts [16–19]. The
published literature has described at least three major
isoforms of palladin, which have molecular weights 200 kDa,
140 kDa, and 90 kDa. The smallest isoform (90 kDa) is a
component of the larger isoforms.
Twenty-eight members from Family X were available for
mutational testing of palladin: 12 individuals with pancreatic
adenocarcinoma (n ¼ 3) or histologically veriﬁed precancer-
ous dysplasia (n¼ 9) and 16 unaffected individuals. Sequence
analysis of palladin identiﬁed a C to T base pair change at
cDNA position 715 in exon 2 that tracks with 100% of the
affected family members and none of the unaffected family
members. The mutation discovered in Family X is contained
in the cDNA clone AB023209 (GenBank; http: / /
www.ncbi.nlm.nih.gov/), which encodes a 4,349 nucleotide
transcript containing 12 exons and encoding a 772-amino
acid protein (90 kDa isoform). The C to T transition causes a
proline (hydrophobic) to serine (hydrophilic) change at
amino acid 239 in palladin (P239S) (Figure 3). The mutant
palladin allele is transcribed and expressed at the RNA level in
the pancreas from Family X PanIN tissue as documented by
qRT-PCR and sequencing.
The P239S base pair substitution is not a known single
nucleotide polymorphism, nor was it detected in the blood of
294 of 295 anonymous controls (the allele frequency was 1 in
590 control alleles). One control blood sample revealed the
mutation; unfortunately, the medical history of this individ-
ual is unknown. The Family X mutation occurs in a region
that is highly conserved across species (Figure 4). This region
of palladin is likely to be functionally important as it encodes
the essential binding site for alpha-actinin, another key
cytoskeletal protein (Figure 5) [20].
Palladin Appears to Be a Proto-Oncogene
Loss-of-heterozygosity studies have shown that regions in
4q can be lost in many different cancers, including
adenocarcinomas of the pancreas [21–24]. However, compa-
rative genomic hybridization studies have not detected any
losses or gains in the 4q32–34 locus in pancreatic cancer [22].
The custom 4q32–34 microarray analysis we performed
suggested that palladin is not likely to be a tumor suppressor
gene (results would reveal loss of expression), but perhaps a
proto-oncogene (results would likely reveal overexpression).
To validate this conclusion, we determined the number of
palladin alleles that were present in sorted precancerous
epithelial tissue from Family X members; if palladin were a
tumor suppressor gene one would anticipate allelic loss. A
custom-made copy number chip (Nimblegen) was used to
measure the number of alleles. The entire palladin copy
number chip was interrogated using epithelial-sorted dys-
plastic pancreas samples from two separate Family X
members. The copy number of the palladin gene was two in
every instance. These ﬁndings, coupled with the RNA over-
Figure 5. Palladin Is an Alpha-Actinin Binding Protein that Controls
Cytoskeletal Formation and Cell Movement
Palladin binds other key proteins such as Ezrin [16]. Previous studies have
shown that Ezrin and S100P are proteins that are abnormally regulated in
pancreatic cancer [35,36].
doi:10.1371/journal.pmed.0040516.g005
Figure 6. Palladin Expression in Primary Cultures of Pancreatic Ductal
Cells Derived from Increasingly Neoplastic Samples
Expression of Palladin RNA increases relative to the degree of precancer
to cancer: normal to PanIN 1 (hyperplasia) to PanIN 3 (carcinoma in situ)
to cancer. Each bar represents epithelial cell cultures from one person.
The PanIN 1 and PanIN 3 lesions (lower left photomicrograph) were
purified from two affected members of Family X. The pancreatic cancer
epithelial cells (lower right photomicrograph) were purified from a
sample of sporadic adenocarcinoma.
doi:10.1371/journal.pmed.0030516.g006
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expression data, suggest that mutated palladin may act as a
proto-oncogene.
Ductal Epithelial Cells Increasingly Overexpressed Palladin
during Neoplastic Progression
Pancreatic adenocarcinoma encompasses a mixture of
tumor cells and a variety of other cell types, especially the
prominent desmoplastic cells common to pancreatic adeno-
carcinomas. To determine whether the palladin gene is
expressed in the pancreatic ductal cells, we examined the
RNA expression in primary HPDE cells with qRT-PCR. Little
to no RNA expression was detected in cells from a normal
pancreatic ductal epithelium; in contrast, increasing expres-
sion was seen in epithelial cells derived from two different
affected Family X individuals who had separate tissue samples
containing precancer (PanIN 1 [hyperplasia] and PanIN 3
[carcinoma in situ]). The greatest overexpression was seen in
ductal epithelial cells taken from a case of sporadic
pancreatic adenocarcinoma. The expression of palladin
increased in primary cultured epithelial cells that were
derived from increasingly advanced neoplasia (PanIN 1
[hyperplasia] , PanIN 3 [carcinoma in situ] , cancer) (Figure
6). The tight correlation between palladin expression and the
neoplastic phenotype present in the ductal epithelial cells
(but not in whole pancreatic tissue) is reminiscent of a dose-
response curve.
The 90 kDa Palladin Is the Major Isoform Expressed in
Human Pancreatic Epithelium
At least three major isoforms of palladin are known, with
molecular weights of 200 kDa, 140 kDa, and 90 kDa. The
smallest isoform (90 kDa) is a component of the larger
isoforms.
We used Western blotting and a polyclonal antibody (ab
621) to assess the protein isoform expressed in pancreatic
ductal epithelium. The 90 kDa isoform is the predominant
form of palladin in pancreatic ductal epithelium and in
pancreatic cancer cell lines (Figure 7).
Palladin and Alpha-Actinin Proteins Are Abnormally
Expressed in Sporadic Pancreatic Cancer Cell Lines
It has been shown that the 90 kDa palladin isoform
colocalizes in stress ﬁbers with several cytoskeletal compo-
nents, such as actin and alpha-actinin [16,19,25]. We examined
the protein expression of these cytoskeletal components in
pancreatic cancer cell lines using Western blotting and a
polyclonal antibody (ab 621) to palladin. Of seven sporadic
pancreatic cancer cell lines (FA6, HPAF, IMIMPC2, SUIT2,
HS766T, PANC-1, and PATU2), ﬁve showed clear protein
overexpression of palladin. Cell lines FA6, HPAF, IMIMPC2,
SUIT2, and PATU2 overexpress palladin protein compared to
the minimal expression in normal HPDE; alpha-actinin was
also abnormally expressed in some of the pancreatic cancer
cell lines, especially in PANC-1, a line that did not show
overexpression changes in palladin protein (Figure 8). These
data suggest that abnormal expression of palladin or its
binding partner, alpha-actinin, is present in six of the seven
pancreatic cancer cell lines we tested.
Mutations in Sporadic Pancreatic Cancer Cell Lines
To evaluate the etiology of palladin overexpression in
sporadic pancreatic cancer, we sequenced the DNA of the
seven sporadic pancreatic cancer cell lines. We identiﬁed a
separate point mutation in a conserved coding region of
palladin present in one of the sporadic pancreatic cancer cell
lines (unpublished data). The new and second mutation
identiﬁed in sporadic pancreatic cancer supports the broader
role of palladin as a proto-oncogene in sporadic pancreatic
cancer.
Expression of the Mutant Palladin Construct Results in an
Abnormal Cellular Cytoskeleton
To investigate if the mutant form of palladin causes
abnormalities in cytoskeletal formation, we cloned the coding
Figure 7. The 90 kDa Palladin Is the Major Isoform Expressed in Human
Pancreatic Epithelium
Proteins were detected using polyclonal antibody to palladin raised in
rabbit (ab 621) in this Western blot. The major palladin isoform expressed
in normal HPDE and cultured epithelial cells is the 90 kDa isoform (solid
arrows). The positive control sample (MSC, human mesenchymal stem
cells) also has the major 90 kDa isoform, but the 140 kDa isoform is also
present (dashed arrow). Mesenchymal stem cells express high levels of
palladin.
doi:10.1371/journal.pmed.0030516.g007
Figure 8. Abnormal Protein Expression of Palladin and Alpha-Actinin
Proteins in Sporadic Pancreatic Cancer Cell Lines
Human mesenchymal cell lysate (hMCL) was used as a positive control
for palladin overexpression. FA6, HPAF, IMIMPC2, SUIT2, and PATU2 are
sporadic pancreatic cancer cell lines that overexpress palladin protein
compared to the minimal expression evident in normal HPDE. Alpha-
actinin is also abnormally expressed in some of the pancreatic cancer cell
lines compared to normal pancreas—especially in PANC-1, one of the
few pancreatic cancer lines that does not show expression changes in
palladin protein.
doi:10.1371/journal.pmed.0030516.g008
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region for the normal human 90 kDa isoform sequence into a
vector with a GFP tag upstream, designated as WT construct.
We then used site-directed mutagenesis to create a C to T
mutation at cDNA position 715 bp, matching the Family X
mutation, designated as FX construct. These constructs were
transfected into HeLa cells to study the phenotypes. Cells
transfected with the wild-type palladin construct displayed
well-organized ﬁlaments that colocalized with the F-actin
bundles (Figure 9A and 9B). When HeLa cells were trans-
fected with the FX construct, however, the GFP-mutant
palladin forms atypical cytoskeletal aggregates. Perhaps the
most distinctive phenotype for the FX construct transfection
was the presence of multiple small ﬂower-like structures in
the cytoplasm: the center of the ﬂower colocalized with F-
actin, while the green ﬂower ‘‘petals’’ of mutated palladin did
not colocalize with F-actin (Figure 9C and 9D). Other cells
that express the mutated palladin contained ﬂecks of protein
in the cytoplasm of the cells that did not colocalize with F-
actin (Figure 9E and 9F). These changes occurred at a much
higher frequency in FX than in WT controls. Cells transfected
with the control GFP empty vector exhibited a green haze
throughout the whole cells (unpublished data). Taken
Figure 9. Expression of Human Wild-Type and P239S Mutant Palladin Constructs in HeLa Cells
(A and B) When HeLa cells were transfected with the human wild-type (WT) palladin construct, filamentous bundles (A) clearly colocalized with the F-
actin (B).
(C and D) In contrast, expression of the mutant P239S Family X (FX) construct resulted in large palladin flower-shaped structures (arrows) in which the
center, but not the petals of the flower, colocalizes with actin.
(E and F) Expression of Family X constructs can also cause small cytoplasmic flecks of palladin that do not colocalize with actin.
HeLa cells overexpressing the empty GFP vector displayed uniform distribution of GFP in the whole cells that did not colocalize with F-actin
(unpublished data). Green, GFP-palladin; red, F-actin; blue, nucleus; yellow, colocalized palladin and F-actin. All figures are at 1003magnification.
doi:10.1371/journal.pmed.0030516.g009
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together, these results suggest that mutant palladin may lose
its ability to fully participate in the regulation of actin
networks, impairing the normal organization of the cytoske-
leton.
Mobility Is Increased in Cells that Express Mutant Palladin
We hypothesized that the cytoskeletal changes in the cells
containing the mutated Family X construct might provide a
cancer phenotype, speciﬁcally increased cell motility. The
cytoskeleton is essential for cell movement, and cell mobility
is important for the invasive nature of cancer cells. HeLa cells
transfected with one of three constructs of palladin (FX, WT
construct, or an empty vector) were individually plated onto a
ﬁbronectin-coated membrane in a transwell chamber, and a
migration assay was performed in a standard fashion [26]. The
cells transfected with the FX construct encoding P239S
mutant palladin outpaced the other cells at every time point.
On average, 33% more cells with the FX construct migrated
through the transwell than the cells with WT construct and
40% more than the cells with the empty vector (Figure 10).
Therefore, P239S palladin expression induces increased cell
motility, consistent with a proposed oncogenic function.
Discussion
The data presented here identify palladin as the mutated
gene in the pancreatic cancer susceptibility locus at 4q32–34,
validate abnormal expression of the gene in a familial
pancreatic cancer kindred, demonstrate RNA overexpression
of this gene in sporadic pancreatic cancers and precancerous
pancreatic tissues, characterize the functional changes
induced by the mutant protein, and suggest that cytoskeletal
abnormalities may be a driving force in pancreatic onco-
genesis.
Palladin is named for a Renaissance architect, Palladio,
because of its role as a key architectural element of the cell.
The function of palladin is to provide a scaffold for
cytoskeletal proteins to bind, forming the actin ﬁlament
complexes necessary for cell morphology, movement, and
differentiation [16]. Abnormalities in the proteins that
arrange the cytoskeleton can result in loss of cellular polarity
(as the cytoskeleton helps direct the location and size of the
nucleus in the cell), changes in cell size, increased invasiveness
(advancement and retraction of the lamellipodia moving the
cell), and abnormal signaling within the cell (the cytoskeleton
scaffold is the docking point for many protein-protein
interactions).
The cytoskeleton is composed of actin bundles (polymer-
ized ﬁlaments) that form the ‘‘tent poles’’ supporting the cell
membrane. The tented cell is held onto the basement
membrane by integrin pegs, with the cytoskeleton directly
connected to the pegs. It is through this normal integrin-
cytoskeleton interaction that the cell is able to distinguish
down from up, providing normal polarity for the cell and a
stationary position [27]. During cell migration, the cross-
linked network of actin ﬁlaments is dynamic, forming and
dissolving through regulation by specialized actin-binding
proteins; in essence these actin-binding proteins form
complexes and a scaffold for the actin to polymerize.
Disruption of the cytoskeleton has been directly linked to
metastatic potential of cancer cells [28]. Speciﬁcally, highly
metastatic cells, which have poor cytoskeletal architecture,
can detach easily from the primary tumor mass, form
transient and weak connections with surrounding connective
tissue, and rapidly migrate through it [29].
To make the discovery of mutated palladin as a cause of
familial pancreatic cancer possible, we had to devise an
endoscopic surveillance program that could detect the
precancerous lesions of the pancreas. This program, to our
knowledge the ﬁrst of its kind, allowed the identiﬁcation of
affected members in Family X, a large kindred with
autosomal dominant, highly penetrant pancreatic cancer.
Genotyping linked the pancreatic susceptibility gene to
4q32–34. A custom microarray of the dense 4q32–34 region
led to the detection of palladin overexpression in Family X
precancer and in sporadic cancer as well. RNA overexpres-
sion of palladin was validated by qRT-PCR in whole tissue of
four precancerous samples (two from members of Family X
and two from non-Family X patients) and in 16 sporadic
cancers. Palladin was also overexpressed in the apparently
‘‘normal’’ tissue adjacent to the cancer. Speciﬁc analysis of
the ductal epithelium revealed an apparent dose-response of
palladin levels in the pancreatic epithelial cells, with increas-
ing RNA expression directly associated with increasing
neoplastic degeneration. These ﬁndings suggest that palladin
plays a very early role in pancreatic tumorigenesis in both the
familial and sporadic forms of the disease and that malignant
progression parallels increased expression of the gene.
Once the candidate gene was identiﬁed, sequencing
veriﬁed that a mutation in the cytoskeleton scaffold gene
palladin causes familial pancreatic cancer in Family X. We
demonstrated that the mutated allele is expressed and that
the consequence of the P239S mutation is a change in amino
acids at the essential alpha-actinin binding site leading to
distinctive changes in the actin bundle morphology. Cells
expressing the P239S mutant palladin protein were found to
be signiﬁcantly more mobile than those expressing wild-type
palladin—theoretically, this capability would provide an
advantage for cells to invade surrounding structures (a
signature feature of cancer).
Palladin is a key scaffold for the cytoskeleton—it binds
several proteins including alpha-actinin [20]. The palladin
mutation in Family X leads to an amino-acid change in the
highly conserved and essential binding site for alpha-actinin
Figure 10. Migration Assay of Palladin Constructs in HeLa Cells
The cells expressing the Family X palladin construct (P239S) migrated
fastest—33% and 42% faster than the cells expressing wild-type (WT)
protein and empty vector constructs, respectively.
doi:10.1371/journal.pmed.0030516.g010
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(Figure 5) [20]. We were able to detect protein expression
abnormalities in either palladin and/or alpha-actinin in six of
seven of the sporadic pancreatic cancer cell lines that we
tested. This change in the palladin/alpha-actinin axis suggests
that these proteins are essential for intact normal cellular
behavior. Speciﬁcally, the alpha-actinin/palladin protein axis
establishes a link between B-integrin subunits and ﬁlamen-
tous actin, holding the cell (through the cytoskeleton) to the
basement membrane (unpublished data) [16,27]. Through this
action, normal pancreatic epithelial cells are uniform in size,
oriented to the basement membrane, and immobile—exactly
the cellular features that are lost in cancer. Alpha-actinin also
plays a role in formation of complex/adhesion plaques; these
plaques are modulated during growth and differentiation
(and reduced in tumor cells) [29]. Mutations in the alpha-
actinin binding site of palladin have not previously been
recognized in human disease, although decreased levels of
normal alpha-actinin in 3T3 cells cause tumorigenesis in
nude mice [30].
Complete loss of palladin function in knock-out mice
results in embryonic lethality [31]. It is apparent that at least
some palladin protein must be present for the cell differ-
entiation and migration events that occur during normal
development. Mutation, rather than complete loss, may lead
to partially intact but imperfect cytoskeleton scaffold
function. In support of this hypothesis, the Family X mutated
constructs revealed that actin cytoskeleton bundles can still
form, although they are aberrant.
It appears likely that palladin is a proto-oncogene. The
protein is overexpressed in sporadic pancreatic cancer, and
even in the normal-appearing tissue adjacent to the cancer.
The molecular events that cause this overexpression are
unknown. Copy number in the palladin region (4q32–34) has
not been reported to be abnormal (either gains or losses) in
previous comparative genomic hybridization analyses [22].
The copy number analysis that we performed in the
precancerous tissue of Family X members revealed two
copies of the gene in every sample tested. These ﬁndings
make it less likely that palladin overexpression is achieved
through ampliﬁcation. Rather, palladin levels might be
elevated through point mutations, such as the one in Family
X, or through other mechanisms, such as promoter region
changes, epigenetic changes, or regulatory factor alterations.
It is also likely that palladin does not act alone. The vast
majority of pancreatic cancers have activation of the K-ras
oncogene, including in Family X [7]. The idea that palladin
and K-ras may work together is an interesting conjecture.
Both of the encoded proteins regulate normal cytoskeletal
activity, and the joint overexpression and activation of these
genes might induce inescapable failure of normal cytoskele-
ton function.
Pancreatic cancer biology has been difﬁcult to probe.
Although genetic defects associated with pancreatic cancer
have been described, a cohesive explanation of pancreatic
neoplastic progression is lacking. The concept that the
cytoskeleton could play a key role in pancreatic cancer
formation is compelling. The critical features that underlie
cancer, including nuclear atypia, loss of cellular polarity,
altered cell morphology, increased mobility, and invasion
into surrounding structures, are all linked to the dynamic
behavior of the cytoskeleton. Moreover, altered cytoskeletal
tension can distort the attached nuclear envelope, rearrang-
ing chromatin/gene positions, subjecting DNA to increased
mutations, and inducing resistance to chemotherapeutic
agents [32–34].
Our data support a key role for palladin in the formation of
sporadic pancreatic cancer and precancer; moreover an
inherited mutation in the palladin gene leads to a highly
penetrant autosomal dominant form of familial pancreatic
cancer. However, the work described is limited to one familial
pancreatic cancer kindred—it will be interesting to evaluate
additional familial pancreatic cancer kindreds for mutational
changes in palladin. The work is also limited in terms of
understanding the role of palladin in sporadic pancreatic
cancer. It seems unlikely that the P239S germline mutation
will be a useful tool in genetic testing for pancreatic cancer
risk in individuals without a strong family history of
pancreatic cancer.
Many questions remain. Do somatic palladin mutations play
a role in pancreatic cancer? How is the gene activated in the
sporadic setting? Are other binding partners of palladin
abnormally expressed or mutated in pancreatic cancer
(sporadic or familial)? How does palladin interact with the
products of oncogenes and tumor suppressor genes in known
pancreatic cancer pathways? Answers to these questions are
crucial to improved methods of early detection and develop
new treatments for this devastating disease.
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Editors’ Summary
Background. Pancreatic cancer is a leading cause of cancer-related
death in the US. Because it causes few symptoms in its early stages,
pancreatic cancer is rarely detected until it has spread (metastasized)
around the body. Pancreatic tumors can occasionally be removed
surgically but the usual treatment is radio- or chemotherapy, and neither
of these is curative; most patients die within a year of diagnosis. As in
other cancers, the cells in pancreatic tumors have acquired genetic
changes (mutations) that allow them to divide uncontrollably (normal
cells divide only to repair damaged tissue). Other mutations alter the
shape of the cells and allow them to migrate into (invade) other areas of
the body. These mutations usually arise randomly—the cells in the
human body are bombarded by chemicals and other agents that can
damage their DNA—and cause ‘‘sporadic’’ pancreatic cancer. But some
people inherit mutated genes that increase their susceptibility to
pancreatic cancer. These people are recognizable because pancreatic
cancer is more common in their families than in the general population.
Why Was This Study Done? The identification of the genes that are
mutated in familial pancreatic cancer might provide insights into how
both inherited and sporadic cancer develops in the pancreas. Such
information could suggest ways to detect pancreatic cancers earlier than
is currently possible and could identify new therapeutic targets for this
deadly disease. Previous work by the researchers who did this study
localized a gene responsible for inherited pancreatic cancer to a small
region of Chromosome 4 in a family in which pancreatic cancer is very
common (Family X). In this study, the researchers identified which of the
genes in this region is likely to be responsible for the susceptibility to
pancreatic cancer of Family X.
What Did the Researchers Do and Find? The researchers made a DNA
microarray (a small chip spotted with DNA sequences) of the 243 genes
in the chromosomal region linked to pancreatic cancer in Family X. They
used this to examine gene expression in dysplastic pancreatic tissue from
a Family X member (pancreatic dysplasia is a precancerous lesion that
precedes cancer), in normal pancreatic tissue, and in samples from
sporadic pancreatic cancers. The most highly overexpressed (compared
to normal tissue) gene in both the Family X tissue and the sporadic
cancers encoded a protein called palladin. Palladin is a component of the
cytoskeleton (a structure that helps to control cell shape and motility)
and it organizes other cytoskeletal components. Next, the researchers
quantified the expression of palladin RNA in an independent set of
normal and cancerous pancreatic samples, and in precancerous
pancreatic tissue taken from Family X members and from people who
inherit pancreatic cancer but who were not in Family X. This analysis
indicated that palladin was overexpressed early in sporadic and inherited
pancreatic cancer development. Sequencing of the palladin gene then
uncovered a mutation in palladin that was present in Family X members
with pancreatic cancer or precancerous lesions but not in unaffected
members. This specific mutation, which probably affects palladin’s
interaction with another cytoskeletal protein called alpha-actinin, was
not found in sporadic cancers although many sporadic cancer cell lines
had abnormal expression of alpha-actinin protein in addition to palladin
protein. Finally, the researchers showed that the introduction of mutated
palladin into a human cell line growing in the laboratory increased its
migration rate and disrupted its cytoskeleton.
What Do These Findings Mean? These results strongly suggest that
mutated palladin is involved in the development of familial pancreatic
cancer. Because genes tend to be inherited in groups, there is still chance
that a mutation in a nearby gene could be responsible for the increased
susceptibility to pancreatic cancer in Family X. However, the data
showing palladin overexpression in sporadic tumors and alterations of
cell behavior in the laboratory after introduction of the mutated gene
make this unlikely. To prove the involvement of palladin in pancreatic
cancer, palladin mutations must now be identified in other familial cases
and the overexpression of palladin in sporadic cancers must be
explained. The results here nevertheless provide an intriguing glimpse
into a potential new mechanism for cancer development in the pancreas
and possibly other tissues, one in which abnormalities in palladin
function or expression (or in the proteins with which it associates) drive
some of the changes in cell migration, shape, and size that characterize
cancer cells.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030516
 US National Cancer Institute, information on pancreatic cancer for
patients and health professionals
 MedlinePlus encyclopedia entry on pancreatic carcinoma
 Cancer Research UK, information for patients about pancreatic cancer
 Johns Hopkins University, information on pancreatic cancer that
includes details on familial cancer
 CancerQuest, information provided by Emory University about how
cancer develops
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